Xencor (NASDAQ:XNCR) Stock Rating Lowered by Wall Street Zen

Xencor (NASDAQ:XNCR) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

XNCR has been the subject of several other research reports. Cantor Fitzgerald upped their target price on shares of Xencor from $40.00 to $42.00 and gave the stock an “overweight” rating in a research note on Thursday, November 6th. Wedbush restated an “outperform” rating and set a $26.00 price target on shares of Xencor in a report on Thursday, November 6th. Barclays upped their price objective on shares of Xencor from $26.00 to $27.00 and gave the stock an “overweight” rating in a research report on Thursday. JPMorgan Chase & Co. dropped their target price on shares of Xencor from $20.00 to $18.00 and set an “overweight” rating on the stock in a research report on Thursday, November 6th. Finally, Royal Bank Of Canada boosted their target price on Xencor from $18.00 to $19.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $25.00.

Xencor Stock Down 5.8%

Shares of Xencor stock opened at $12.77 on Friday. Xencor has a 52 week low of $6.92 and a 52 week high of $18.69. The business has a 50 day moving average price of $13.15 and a 200-day moving average price of $12.78. The company has a market cap of $936.55 million, a PE ratio of -10.30 and a beta of 0.98.

Xencor (NASDAQ:XNCR) last announced its earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.55. The company had revenue of $28.24 million for the quarter, compared to analysts’ expectations of $29.97 million. Xencor had a negative return on equity of 14.62% and a negative net margin of 73.20%.Xencor’s quarterly revenue was down 46.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.62) earnings per share. As a group, research analysts anticipate that Xencor will post -3.68 EPS for the current year.

Insider Activity at Xencor

In related news, VP John R. Desjarlais sold 73,367 shares of Xencor stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $15.72, for a total value of $1,153,329.24. Following the completion of the sale, the vice president owned 236,574 shares of the company’s stock, valued at approximately $3,718,943.28. This trade represents a 23.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Bassil I. Dahiyat sold 114,377 shares of the company’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $15.71, for a total transaction of $1,796,862.67. Following the sale, the chief executive officer directly owned 466,635 shares in the company, valued at approximately $7,330,835.85. This trade represents a 19.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 4.76% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Hantz Financial Services Inc. increased its stake in Xencor by 209.1% during the 3rd quarter. Hantz Financial Services Inc. now owns 3,187 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 2,156 shares in the last quarter. GAMMA Investing LLC raised its stake in Xencor by 77.1% during the 3rd quarter. GAMMA Investing LLC now owns 3,328 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 1,449 shares during the last quarter. Farther Finance Advisors LLC bought a new position in shares of Xencor during the 3rd quarter valued at $44,000. Tower Research Capital LLC TRC lifted its holdings in shares of Xencor by 118.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 3,018 shares during the period. Finally, Federated Hermes Inc. boosted its stake in shares of Xencor by 114.3% in the 3rd quarter. Federated Hermes Inc. now owns 3,947 shares of the biopharmaceutical company’s stock worth $46,000 after buying an additional 2,105 shares during the last quarter.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.